Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008

Novartis Vaccines129 enrolled

Overview

Due to antigenic changes of influenza viruses, the virus strains used in influenza vaccines are adjusted every year according to WHO and CPMP recommendations. Immunogenicity and tolerability of the newly composed vaccines are subject for evaluation in a yearly clinical trial in non-elderly adults and elderly subjects (CPMP/BWP/214/96).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

129

Conditions

Influenza

Interventions

Surface antigen inactivated influenza vaccineBIOLOGICAL

1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition

Eligibility

Sex: ALLMin age: 18 YearsMax age: 84 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy Subjects eligible for enrollment into this study are male and female adult volunteers Exclusion Criteria: * Any serious disease

Locations (1)

The Health Centre

Suffolk, United Kingdom

Outcomes

Primary Outcomes

evaluate the antibody response to each influenza vaccine antigen

Time frame: 21 days post-immunization

Secondary Outcomes

Safety and tolerability of the study vaccine in the study population

Time frame: Throughout the study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.